Jen joined CoA Therapeutics in December 2021 as VP, Regulatory Affairs leading the regulatory affairs team. Prior to joining CoA Therapeutics, Jen led the marketing applications for Nulibry at Origin Biosciences, Inc., an affiliate of BridgeBio since August 2019. With over 20 years of regulatory experience, Jen has extensive exposure in drug development across more than 10 therapeutic areas and has developed small molecules, biologics, and gene therapies. Jen has focused on rare diseases for approximately half of her regulatory career, finding the development of new treatments for patients with rare diseases rewarding and hopes to continue to do so for years to come. She received her degree in Animal Sciences from the University of Maryland.